Invitation to Presentation of Immunovia's Interim Report January - March 2020 on April 28, 2020

Invitation to Presentation of Immunovia's Interim Report January - March 2020 on April 28, 2020

PR Newswire

LUND, Sweden, April 22, 2020

LUND, Sweden, April 22, 2020 /PRNewswire/ -- Immunovia invites to a teleconference (in English) for investors, analysts and media on Tuesday, April 28th, 2020 at 16:30 CET. Immunovia will publish the company's interim report on April 28th, 2020 at 16:00 CET.

Mats Grahn, CEO will present Immunovia and comment on the interim report for the period January - March 2020 followed by a Q&A session.

Please call in a few minutes in advance. To attend, please dial-in at one of the numbers below and provide the conference code Immunovia to the operator:

Conference Numbers:

Sweden: +46-(0)-8-50520424

United Sates: +1-212-999-6659

France: +33-(0)-1-7099-4740

Denmark: +45-3271-4573

Germany: +49-(0)-69-7104-45598

Spain: +34-91-788-9854

Netherlands: +31-(0)-20-794-8426

Norway: +47-2-156-3318

Austria: +43-(0)-12530807

Switzerland: +41-(0)-43-456-9986

UK (standard international access): +44-(0)-20-3003-2666

Conference Code: (to provide to the operator) Immunovia

Immunovia Webcast:

There will be an MP3-file available at Immunovia's webpage under Investors/Financial Reports ( for those who want to listen to the telephone conference afterwards. The file will be available within two hours after the conference has ended.

About Immunovia
Immunovia AB is a diagnostic company that is developing and commercializing highly accurate blood tests for the early detection of cancer and autoimmune diseases based on Immunovia's proprietary test platform called IMMray™. Tests are based on antibody biomarker microarray analysis using advanced machine-learning and bioinformatics to single-out a set of relevant biomarkers that indicate a certain disease. Thus, forming a unique "disease biomarker signature".

The company was founded in 2007, based on cancer studies and ground-breaking research in the Department of Immuntechnology at Lund University and CREATE Health Cancer Center, Sweden.

The first product, IMMray™ PanCan-d, is undergoing clinical evaluation in some of the world's largest clinical studies for pancreatic cancer, PanFAM-1, PanSYM-1 and PanDIA-1 and is currently entering the final validation for sales start Q3 2020. When validated, IMMray™ PanCan-d will be the first blood-based test for early diagnosis of pancreatic cancer on the market, with a potential to significantly improve patient survival and outcome.

Immunovia's shares (IMMNOV) are listed on Nasdaq Stockholm. For more information, please visit


For more information, please contact:

Julie Silber, Director of Investor Relations, Immunovia

Tel: +46-7-93-486-277

This information was brought to you by Cision,c3094531

The following files are available for download:


Voltar noticias em Inglês